Comparison of tranexamic acid versus Kligman’s application in the treatment of macular amyloidosis
Phase 2
- Conditions
- Macular amyloidosis.Other amyloidosisE85.8
- Registration Number
- IRCT20150529022468N5
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Age range 18 to 50 years
Suffering from macular amyloidosis
Exclusion Criteria
Pregnant or lactating women
History of cardiovascular disease
Keloid patients
Patients taking anticoagulants
Any allergy to the study drugs
History of bleeding disorder
Topical treatment three months before entering the study
No consent to participate in the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Skin darkness. Timepoint: 4, 8 and 12 weeks after start and 3 months after finishing the treatment. Method of measurement: The Visioface device, the third physician's opinion, and the patient's opinion.
- Secondary Outcome Measures
Name Time Method